Chinook Therapeutics (KDNY) Stock Forecast, Price Target & Predictions
KDNY Stock Forecast
Chinook Therapeutics stock forecast is as follows: an average price target of $30.00 (represents a -25.72% downside from KDNY’s last price of $40.39) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KDNY Price Target
The average price target for Chinook Therapeutics (KDNY) is $30.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $30.00. This represents a potential -25.72% downside from KDNY's last price of $40.39.
KDNY Analyst Ratings
According to 4 Wall Street analysts, Chinook Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KDNY stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 1 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Chinook Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 05, 2022 | Wells Fargo | - | - | 27.33% | -25.72% |
The latest Chinook Therapeutics stock forecast, released on Dec 05, 2022 by Wells Fargo company, set a price target of $30.00, which represents a 27.33% increase from the stock price at the time of the forecast ($23.56), and a -25.72% decrease from KDNY last price ($40.39).
Chinook Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $40.39 | $40.39 | $40.39 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Chinook Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Chinook Therapeutics's last price of $40.39. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 14, 2023 | BTIG | Buy | Initialise | |
| Jun 14, 2023 | JonesTrading | Buy | Initialise | |
| Jun 12, 2023 | Guggenheim | Neutral | Downgrade | |
| Dec 05, 2022 | Wells Fargo | Overweight | Initialise |
Chinook Therapeutics's last stock rating was published by BTIG on Jun 14, 2023. The company Initialise its KDNY rating from "null" to "Buy".
Chinook Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | - | - | 1730.27% | Buy |
| PLRX | Pliant Therapeutics | - | - | 205.93% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 182.80% | Buy |
| GPCR | Structure Therapeutics | - | - | 176.56% | Buy |
| KALV | KalVista Pharmaceuticals | - | - | 123.35% | Buy |
| KURA | Kura Oncology | - | - | 122.22% | Buy |
| VRDN | Viridian Therapeutics | - | - | 87.72% | Buy |
| SWTX | SpringWorks Therapeutics | - | - | 72.55% | Buy |
| ASND | Ascendis Pharma | - | - | 46.53% | Buy |
| PCVX | Vaxcyte | - | - | 40.05% | Buy |
| DICE | DICE Therapeutics | - | - | 26.18% | Buy |
| RNA | Avidity Biosciences | - | - | 26.01% | Buy |
| CRNX | Crinetics Pharmaceuticals | - | - | 25.12% | Buy |
| TVTX | Travere Therapeutics | - | - | 19.18% | Buy |
| NUVL | Nuvalent | - | - | 17.53% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | - | - | 6.84% | Buy |
| ACLX | Arcellx | - | - | -8.23% | Buy |
| CERE | Cerevel Therapeutics | - | - | -25.49% | Buy |
| KDNY | Chinook Therapeutics | - | - | -25.72% | Buy |